Tocagen Inc., of San Diego, reported updated data for Toca 511 (vocimagene amiretrorepvec) in combination with Toca FC (extended-release 5-flurocytosine) for the treatment of recurrent high-grade glioma at the International Oncolytic Virus Meeting in Vancouver, British Columbia.